Emergence of fluoroquinolone resistance in strains of Vibrio cholerae isolated from hospitalized patients with acute diarrhea in Calcutta, India.

The problem of antimicrobial resistance in microorganisms causing diarrheal diseases in both developed and developing countries continues to be alarming (6). Toxigenic Vibrio cholerae is the causative agent of the life-threatening disease cholera. Plasmid-encoded high-level resistance to ampicillin, kanamycin, streptomycin, sulfonamide, tetracycline, trimethoprim, and gentamicin has been demonstrated among strains of V. cholerae O1 isolated from Bangladesh, India, and Latin America (7, 9). Fluoroquinolones have excellent activity against all pathogenic Vibrio species, and clinical trials have found norfloxacin to be effective for the treatment of cholera in adults and in children (2, 3). Antimicrobial susceptibility analysis of 212 strains of V. cholerae isolated from patients with acute watery diarrhea admitted to the Infectious Diseases Hospital, Calcutta, India, between March 1996 and September 1996 was performed by the disk diffusion technique (1) with commercial discs (Hi-Media, Bombay, India). Characterization of strains as susceptible, intermediately resistant, or resistant was based on the size of the inhibition zones around each disc according to the manufacturer’s instructions, which matched the interpretive criteria recommended by World Health Organization (8). Strains showing intermediate zones of inhibition were interpreted as resistant on the basis of previous MIC studies conducted with V. cholerae (9). MICs of norfloxacin and ciprofloxacin were determined by the agar dilution method with Mueller-Hinton agar according to standard procedures (8). V. cholerae strains resistant to norfloxacin and cirprofloxacin began appearing in late 1995 (5), and strains resistant to fluoroquinolones started increasing from July 1996, with a steady decrease in the zone of inhibition. To date, resistance to norfloxacin and ciprofloxacin is restricted to the non-O1 non-O139 serogroups of V. cholerae (Table 1). This prompted us to examine the activity of three more fluoroquinolones against V. cholerae non-O1 non-O139 strains (Table 1). Of the 69 strains examined, 14.5, 10.1, and 11.6% showed reistance to lomefloxacin, pefloxacin, and ofloxacin, respectively. Among the O1 and O139 serogroups isolated in 1996, a contrasting pattern of resistance to different antibiotics was observed, with the most common (71%) drug resistance in V. cholerae O1 strains being to ampicillin, chloramphenicol, co-trimoxazole, furazolidone, neomycin, nalidixic acid, and streptomycin, while the most common (66%) resistance pattern in V. cholerae O139 was ampicillin, furazolidone, neomycin, and streptomycin. In this study, the agar dilution breakpoints adopted by the Centers for Disease Control and Prevention, Atlanta, Ga. (MICs of $1.0 mg of ciprofloxacin and norfloxacin per ml), were used for interpretation of resistance to these agents (4). Among the fluoroquinolones, MICs of the widely used norfloxacin and ciprofloxacin for the resistant strains of V. cholerae non-O1 non-O139 ranged from 3.125 to .100 and 3.125 to 75 mg/ml, respectively; MICs of norfloxacin were .100 mg/ml for 5 strains, and the MIC of ciprofloxacin was about 50 mg/ml. MICs for the susceptible strains of V. cholerae non-O1 nonO139 ranged from #0.0245 to 0.39 mg/ml for ciprofloxacin and 0.049 to 0.78 mg/ml for norfloxacin. A trend of increasing MICs for susceptible strains isolated after June 1996 was observed. All strains, with the exception of one in each case, were concurrently resistant to both norfloxacin and ciprofloxacin. The emergence of fluoroquinolone-resistant V. cholerae is ominous and may be a prelude to other pathogenic Vibro species acquiring resistance, which will create major problems in treating severe cases of diarrhea when an antibiotic intervention is deemed necessary.